Results 201 to 210 of about 10,900 (261)

Palivizumab

Drugs, 1999
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
  +5 more sources

Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10‐year follow‐up study

Pediatric Pulmonology, 2023
Respiratory syncytial virus (RSV) causes not only infantile recurrent wheezing but also the development of asthma. To investigate whether palivizumab, an anti‐RSV monoclonal antibody, prophylaxis given to preterm infants during the first RSV season ...
Masahiko Kato, Hiroyuki Mochizuki, Yuichi Kama, Satoshi Kusuda, Kenji Okada, Shigemi Yoshihara, Hiroyuki Furuya, Eric A F Simoes   +7 more
semanticscholar   +1 more source

In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.

Virology, 2023
BACKGROUND Monoclonal antibody (palivizumab), intravenous immune globulin (IGIV), or respiratory syncytial virus (RSV)-polyclonal-hyperimmune-globulin (RSV-IG as Respigam®, RI-001, RI-002) are used with ribavirin in RSV-infected immunocompromised ...
Kacy A. Ramirez, J. Mond, J. Papenburg, G. Boivin, B. Gilbert, A. Falsey, B. Bagga, J. Devincenzo   +7 more
semanticscholar   +1 more source

Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab

American Journal of Perinatology, 2022
This article aims to assess the real-world effectiveness of palivizumab immunoprophylaxis against respiratory syncytial virus (RSV)-associated hospitalization (RSVH) rates in otherwise healthy moderate/late preterm infants and discuss the role of ...
P. Manzoni, Eugenio Baraldi, M. Luna, C. Tzialla   +3 more
semanticscholar   +1 more source

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children

Expert Review of Anti-Infective Therapy
Introduction Respiratory syncytial virus (RSV) causes significant morbidity and mortality in young children. For 25 years, palivizumab has been the only effective pharmaceutical RSV preventive.
X. Carbonell-Estrany, Eric A F Simões, L. Bont, P. Manzoni, H. Zar, Anne Greenough, O. Ramilo, Renato T. Stein, B. Law, A. Mejías, Manuel Sánchez Luna, P. Checchia, L. Krilov, M. Lanari, Ron Dagan, B. Fauroux, B. Resch, Terho Heikkinen, Joseph B. Domachowske, J. Wildenbeest, Federico Martinón-Torres, R. Thwaites, Merih Çetinkaya, Adel S. Alharbi, C.E. Rodriguez-Martinez, D. Noyola, Asiah Kassim, Satoshi Kusuda, Ji-Man Kang, B. Rodgers-Gray, A. Platonova, Fungwe Jah, Bosco A Paes   +32 more
semanticscholar   +1 more source

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.

Pediatrics
BACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care ...
Deidre Wilkins, U. Wählby-Hamrén, Yue Chang, Lindsay Clegg, Joseph B. Domachowske, J. Englund, William J. Muller, Amanda Leach, Elizabeth J. Kelly, T. Villafana   +9 more
semanticscholar   +1 more source

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Cochrane Database of Systematic Reviews
RATIONALE Respiratory viruses are the leading cause of lower respiratory tract infection and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
L. Garegnani, P. Roson Rodriguez, C. E. Escobar Liquitay, Ignacio Esteban, J. Franco   +4 more
semanticscholar   +1 more source

Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals

Pediatric Pulmonology, 2022
To evaluate the impact of immunoprophylaxis with palivizumab in preterm infants less than 35 weeks in terms of hospitalization rate, intensive care unit requirement, and mortality.
Clara Galvis, A. Colmenares, Lina Cabrales, L. Ibatá, J. Marulanda, O. Ovalle, Dionisio Puello, Catherine Rojas, Martha Africano, A. Ballesteros, H. Posso   +10 more
semanticscholar   +1 more source

Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study

American Journal of Respiratory and Critical Care Medicine, 2017
Hiroyuki Mochizuki, Satoshi Kusuda, Shigemi Yoshihara   +2 more
exaly   +2 more sources

Efficacy of palivizumab immunoprophylaxis for reducing severe RSV outcomes in children with immunodeficiencies: A systematic review.

Journal of the Pediatric Infectious Diseases Society
BACKGROUND Palivizumab is recommended for prevention of severe respiratory syncytial virus (RSV) disease in immunocompromised children, despite a lack of strong supporting evidence. The recent approval of substitute RSV-neutralizing monoclonal antibodies
F. Reicherz, B. Abu-Raya, Omolabake Akinseye, S. Rassekh, Matthew O. Wiens, Pascal M. Lavoie   +5 more
semanticscholar   +1 more source